Zilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin (anti-ROR1) induces apoptosis. Zilovertamab vedotin (anti-ROR1) can be used in research of cancer. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Zilovertamab vedotin (anti-ROR1) (Ab183321) - Flow Cytometry Flow Cytometry analysis of A549 cells labelling ROR1 (red) with Zilovertamab vedotin (anti-ROR1) (Ab183321). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Zilovertamab vedotin (anti-ROR1) (Ab183321) - ELISA Immobilized Recombinant Human ROR1 protein (rp176297) at 1.0 μg/mL can bind Zilovertamab vedotin (anti-ROR1) (Ab183321) with the EC
₅₀
of 24.23 ng/mL.
Zilovertamab vedotin (anti-ROR1) (Ab183321) - SEC The purity of Zilovertamab vedotin (anti-ROR1) (Ab183321) is more than 95% verified by HPLC.